Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243753 | 0.84 | HSD11B1 (0.72) | HSD11B1TP53MAPTKMT2APOLB | |
| SCHEMBL609816 | 0.81 | HSD11B1 (0.57) | HSD11B1ALDH1A1HTTRAB9ATP53 | |
| SCHEMBL609817 | 0.81 | HSD11B1 (0.57) | HSD11B1ALDH1A1HTTRAB9ATP53 | |
| SCHEMBL4960486 | 0.81 | HSD11B1 (0.57) | HSD11B1ALDH1A1HTTRAB9ATP53 | |
| SCHEMBL5250238 | 0.80 | MEN1 (0.60) | KDM4EALDH1A1HTTRAB9ACYP2C19 | |
| SCHEMBL5247343 | 0.80 | HSD11B1 (0.70) | HSD11B1HTTTP53MAPTMEN1 | |
| SCHEMBL611305 | 0.80 | HSD11B1 (0.98) | HSD11B1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL4142798 | 0.80 | HSD11B1 (0.90) | HSD11B1ALDH1A1RAB9ATP53MAPT | |
| SCHEMBL4962053 | 0.80 | HSD11B1 (0.98) | HSD11B1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL6488610 | 0.80 | HSD11B1 (0.69) | HSD11B1KDM4EALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885KDM4E 3167/4885ALDH1A1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.